Open Access Peer-reviewed Perspective

Perspectives on chemotherapy-induced toxicities in pancreatic cancer

Main Article Content

Henu Kumar Verma corresponding author
Tarun Sahu
LVKS Bhaskar


Despite breakthroughs in screening, identification, and therapy, pancreatic cancer (PC) remains a serious issue in cancer-related mortality. This comprehensive review investigates the long-term and latent effects of chemotherapy in PC, focusing on commonly used medicines such as gemcitabine, docetaxel, irinotecan, nab-paclitaxel, and others. Gemcitabine, a common PC medication, causes a variety of adverse effects, including myelosuppression and weariness. Combination therapy, such as docetaxel and irinotecan, enhance toxicity, resulting in problems such as neutropenia and gastrointestinal difficulties. Significantly, chemotherapy-related complications, such as thrombosis and cardiac difficulties connected to paclitaxel, present serious concerns. Erlotinib, gefitinib, vatalanib, and sunitinib studies show significant side effects. Despite ongoing challenges, determining the causes of the low objective response rate in gemcitabine-refractory patients remains challenging. The study emphasizes the importance of future advances in cancer etiology, arguing for large, straightforward studies examining combination chemotherapies to improve tolerance and minimize chemotherapy-induced sequelae. This overview serves as a thorough guide for physicians, researchers, and policymakers as they navigate the complex terrain of PC chemotherapy, providing significant insights to improve patient care.

pencretic cancer, chemoresistance, toxicities

Article Details

How to Cite
Verma, H. K., Sahu, T., & Bhaskar, L. (2024). Perspectives on chemotherapy-induced toxicities in pancreatic cancer. Current Cancer Reports, 5(1), 181-186.


  1. Grossberg AJ, Chu LC, Deig CR, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA: A Cancer Journal for Clinicians. 2020, 70(5): 375-403.
  2. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA: A Cancer Journal for Clinicians. 2016, 66(4): 271-289.
  3. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer. 2018, 144(8): 1941-1953.
  4. Shah K, Rawal RM. Genetic and Epigenetic Modulation of Drug Resistance in Cancer: Challenges and Opportunities. Current Drug Metabolism. 2020, 20(14): 1114-1131.
  5. Verma HK, Falco G, Bhaskar LVKS. Molecular Signaling Pathways Involved in Gastric Cancer Chemoresistance. Diagnostics and Therapeutic Advances in GI Malignancies. Published online 2020: 117-134.
  6. Zeng, Pöttler, Lan, et al. Chemoresistance in Pancreatic Cancer. International Journal of Molecular Sciences. 2019, 20(18): 4504.
  7. Lee HS, Park SW. Systemic Chemotherapy in Advanced Pancreatic Cancer. Gut and Liver. 2016, 10(3).
  8. Min YJ, Joo KR, Park NH, et al. Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer. The Korean Journal of Internal Medicine. 2002, 17(4): 259-262.
  9. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial. Journal of Clinical Oncology. 2005, 23(15): 3509-3516.
  10. Lee MG, Lee SH, Lee SJ, et al. 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy. Chemotherapy. 2013, 59(4): 273-279.
  11. You MS, Ryu JK, Choi YH, et al. Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer. Gut and Liver. 2018, 12(6): 728-735.
  12. Ko A. Erlotinib in the treatment of advanced pancreatic cancer. Biologics: Targets & Therapy. Published online March 2008: 83.
  13. Siddiqui NS, Godara A, Byrne MM, et al. Capecitabine for the treatment of pancreatic cancer. Expert Opinion on Pharmacotherapy. 2019, 20(4): 399-409.
  14. Ko AH, Dito E, Schillinger B, et al. Excess Toxicity Associated with Docetaxel and Irinotecan in Patients with Metastatic, Gemcitabine-Refractory Pancreatic Cancer: Results of a Phase II Study. Cancer Investigation. 2008, 26(1): 47-52.
  15. ZHANG DX, DAI YD, YUAN SX, et al. Prognostic factors in patients with pancreatic cancer. Experimental and Therapeutic Medicine. 2011, 3(3): 423-432.
  16. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial. Journal of Clinical Oncology. 2011, 29(34): 4548-4554.
  17. John P, Butler H, Saif MW. Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer. Anticancer Research. 2014, 34(12): 7267-7270.
  18. Syrigos KN, Michalaki B, Alevyzaki F, et al. A phase-II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer. Anticancer research. 2002, 22(6B): 3583-3588.
  19. Ulrich-Pur H, Raderer M, Verena Kornek G, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. British Journal of Cancer. 2003, 88(8): 1180-1184.
  20. Carvajal RD, Tse A, Shah MA, et al. A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer. Pancreatology. 2009, 9(4): 404-409.
  21. Boeck S, Weigang-Köhler K, Fuchs M, et al. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Annals of Oncology. 2007, 18(4): 745-751.
  22. Stathopoulos G, Boulikas T, Vougiouka M, et al. Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: A phase I-II study. Oncology Reports. Published online May 1, 2006.
  23. Tschoep KE, Boeck S, Berger F, et al. Regional hyperthermia (RHT) combined with gemcitabine (GEM) + cisplatin (CIS) in patients with GEM-refractory advanced pancreatic cancer: Results of the ESHO phase II trial. Journal of Clinical Oncology. 2008, 26(15$_$suppl): 4635-4635.
  24. Verma HK, Kampalli PK, Lakkakula S, et al. A Retrospective Look at Anti-EGFR Agents in Pancreatic Cancer Therapy. Current Drug Metabolism. 2020, 20(12): 958-966.
  25. Lakkakula BVKS, Farran B, Lakkakula S, et al. Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles. Seminars in Cancer Biology. 2019, 56: 149-167.
  26. Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer. Journal of Clinical Oncology. 2007, 25(30): 4787-4792.
  27. Ignatiadis M, Polyzos A, Stathopoulos GP, et al. A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer. Oncology. 2006, 71(3-4): 159-163.
  28. Brell JM, Matin K, Evans T, et al. Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer. Oncology. 2009, 76(4): 270-274.
  29. Dragovich T, Laheru D, Dayyani F, et al. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemotherapy and Pharmacology. 2014, 74(2): 379-387.
  30. O’Reilly EM, Niedzwiecki D, Hollis DR, et al. A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. Journal of Clinical Oncology. 2008, 26(15$_$suppl): 4515-4515.
  31. Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. International Journal of Molecular Sciences. 2017, 18(7): 1338.
  32. Javle MM, Shroff RT, Xiong H, et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 2010, 10(1).
  33. Kagawa S, Takano S, Yoshitomi H, et al. Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. Journal of Surgical Research. 2012, 178(2): 758-767.
  34. Koltai T, Reshkin SJ, Carvalho TMA, et al. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. Cancers. 2022, 14(10): 2486.
  35. Turco C, Jary M, Kim S, et al. Gemcitabine-Induced Pulmonary Toxicity: A Case Report of Pulmonary Veno-Occlusive Disease. Clinical Medicine Insights: Oncology. 2015, 9: CMO.S26537.
  36. Baig J, Shokouh-Amiri M, Chan J, et al. The Spectrum of Pulmonary Toxicity in Pancreatic Cancer Patients Receiving Gemcitabine Combination Chemotherapy. Case Reports in Oncology. 2019, 12(2): 506-512.
  37. Hama Y. Exacerbation of gemcitabine-related pneumonia during radiotherapy for extrapulmonary lesion. International Cancer Conference Journal. 2016, 6(1): 35-37.
  38. Liu G, Li G, Zhao H. Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta‐Analysis. Journal of Cellular Biochemistry. 2017, 119(1): 511-523.
  39. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023, 73(1): 17-48.
  40. Hamidi H, Lu M, Chau K, et al. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. British Journal of Cancer. 2014, 111(9): 1788-1801.